Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence

Emilio Sacco, Marco Racioppi, Pierfrancesco Bassi, Riccardo Bientinesi, Daniele Tienforti, Gaetano Gulino, Daniele D'Agostino, Matteo Vittori

Risultato della ricerca: Contributo in rivistaArticolo in rivista

35 Citazioni (Scopus)

Abstract

Overactive bladder (OAB) and urinary incontinence, although not life-threatening, are very bothersome chronic health conditions. The limitations of current pharmacological treatment urge the need for novel drugs with alternative mechanisms of action. Huge efforts in this area of research led to the synthesis of several selective and potent β3-adrenoceptor agonists that gained relevance through research during the late 80s and 90s. Mirabegron was the first compound of this new class of drugs that showed preclinical efficacy in several models of storage bladder dysfunction, together with a favorable human pharmacological profile. Having passed the proof-of-concept stage, an extensive clinical development and pharmacology program was performed during the last 10 years, involving >10,000 individuals, before mirabegron was granted marketing approval.
Lingua originaleEnglish
pagine (da-a)433-448
Numero di pagine16
RivistaExpert Opinion on Drug Discovery
Volume9
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Acetanilides
  • Adrenergic beta-3 Receptor Agonists
  • Animals
  • Humans
  • Receptors, Adrenergic, beta-3
  • Thiazoles
  • Urinary Bladder, Overactive
  • Urinary Incontinence
  • Urinary Tract
  • Urological Agents

Fingerprint Entra nei temi di ricerca di 'Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence'. Insieme formano una fingerprint unica.

Cita questo